Ua hoʻolaha ʻo InxMed Co., Ltd. ua hāʻawi ʻia ʻo IN0018 me ka Breakthrough Therapy Designation e ka China National Medical Products Administration. Hoʻokumu ʻia kēia koho i nā hopena o kahi hoʻokolohua lapaʻau Phase Ib/II o IN10018 no ka maʻi maʻi ovarian-resistant platinum, me ka hōʻailona i manaʻo ʻia no ka mālama ʻana i ka maʻi maʻi ovarian-resistant platinum i hui pū ʻia me PEG-liposomal doxorubicin. Hoʻolālā ʻo InxMed e hōʻike i nā ʻikepili hou aʻe ma IN10018 ma ka Annual Meeting of the American Society of Clinical Oncology i Iune 2022 a hoʻomaka i kahi hoʻokolokolo pivotal i ka hapa lua o ka makahiki.
Ke manaʻo nei ʻo Breakthrough Therapy Designation e kōkua i nā ʻoihana e hana pū me nā luna e hoʻokē ʻai i ka noiʻi, hoʻomohala, a me ka ʻae ʻana i nā lāʻau lapaʻau hou e hiki ke hoʻoponopono i nā pono olakino. Ua loaʻa iā IN10018 ka inoa wikiwiki mai ka US Food and Drug Administration no ka mālama ʻana i nā poʻe maʻi me ka platinum-resistant ovarian cancer i ʻAukake 2021. E hoʻokō ʻo InxMed i nā manaʻolana kiʻekiʻe a hoʻoikaika e hāʻawi i nā pono o nā lāʻau lapaʻau hou i nā poʻe maʻi me ka wikiwiki. .
ʻO FAK he tyrosine kinase non-receptor a me ka transmitter e hana koʻikoʻi i ka adhesion cell, migration, a me ka hoʻoponopono. Hōʻike ia i ka upregulation hōʻike i nā ʻano tumora he nui. Ua ʻike nā mea noiʻi ʻo ke kāohi ʻana i ke ala hōʻailona FAK hiki ke hoʻohuli maikaʻi i ka chemotherapy i hāʻule mua ʻole a me ka lāʻau lapaʻau i hoʻokumu ʻia e ke kūʻē ʻana i ka lāʻau a hoʻonui i ka pane a me ka maikaʻi o ka immunotherapy no nā ʻōpū paʻa.
ʻO IN10018 kahi mea hoʻokūkū ikaika a koho nui i ka adenosine triphosphate hoʻokūkū FAK inhibitor, a loaʻa iā InxMed kāna hoʻomohala honua a me nā kuleana hana ʻoihana. Ua alakaʻi ʻo InxMed Nanjing Translational Medicine Center i ka noiʻi ʻimi noiʻi mua loa ma nā pahuhopu IN10018 a me FAK a ua hoʻopuka i nā hopena noiʻi ma nā puke puke haʻawina kaulana. Ua hōʻike ka ʻikepili mua o IN10018 i kona palekana a me ka pono i nā ʻano maʻi maʻi he nui, a ua hōʻike nā hopena noiʻi hou a me nā ʻikepili preclinical hiki i ka IN10018 ke kūpono i nā lāʻau lapaʻau hui. Manaʻo ʻia e lanakila i ka pale fibrosis pili i ka tumo a hoʻomaikaʻi i ka pale kūloko, a no laila hiki ke hana ma ke ʻano he mole mole heleuma koʻikoʻi i ka synergy me nā ʻano therapeutic like ʻole me ka immunotherapy, chemotherapy, a me ka lāʻau lapaʻau.
Ua hoʻokumu ʻo InxMed i kahi papahana hoʻomohala lapaʻau honua no IN10018. Hoʻolālā ʻia nā hoʻokolohua lapaʻau i kēia manawa ma US a me Kina no ka platinum-resistant ovarian cancer, NRAS mutant metastatic melanoma, triple-negative breast cancer, head and neck cancer, pancreatic cancer, a me nā maʻi ʻokoʻa paʻa ʻē aʻe i nele i ka mālama pono.
He aha e lawe ʻia mai kēia ʻatikala:
- Hoʻolālā ʻo InxMed e hōʻike i nā ʻikepili hou aʻe ma IN10018 ma ka Annual Meeting of the American Society of Clinical Oncology i Iune 2022 a hoʻomaka i kahi hoʻokolokolo pivotal i ka hapa lua o ka makahiki.
- Hoʻokumu ʻia kēia koho ʻana i nā hopena o kahi hoʻokolohua lapaʻau Phase Ib/II o IN10018 no ka maʻi maʻi ovarian-resistant platinum, me ka hōʻailona i manaʻo ʻia no ka mālama ʻana i ka maʻi maʻi ovarian pale platinum i hui pū ʻia me PEG-liposomal doxorubicin.
- Ua hōʻike ʻia ka ʻikepili lapaʻau mua ma IN10018 i kona palekana a maikaʻi hoʻi i nā ʻano maʻi maʻi he nui, a ua hōʻike nā hopena noiʻi hou a me nā ʻikepili preclinical e hiki nō hoʻi i ka IN10018 ke hana maikaʻi i nā lāʻau lapaʻau hui.
